As there is the limitation of this being a case report, further clinical studies will be required to evaluate the efficacy and safety of combination therapy with entecavir and short-term intravenous administration of IFN-β 3 MIU twice per day to prevent the development of HBV reactivation-related hepatitis. Here, IFNB1 is linked to hepatitis A virus infection.